TY - JOUR
TI - Prognostic value of serum free light chain ratio at diagnosis in
multiple myeloma
AU - Kyrtsonis, Marie-Christine
AU - Vassilakopoulos, Theodoros P.
AU - Kafasi,
AU - Nicoletta
AU - Sachanas, Sotirios
AU - Tzenou, Tatiana
AU - Papadogiannis,
AU - Argiroula
AU - Galanis, Zacharoula
AU - Kalpadakis, Christina
AU - Dimou,
AU - Maria
AU - Kyriakou, Elias
AU - Angelopoulou, Maria K.
AU - Dimopoulou,
AU - Maria N.
AU - Siakantaris, Marina P.
AU - Dimitriadou, Evangelia M. and
AU - Kokoris, Styliani I.
AU - Panayiotidis, Panayiotis
AU - Pangalis,
AU - Gerassimos A.
JO - British Journal of Haematology
PY - 2007
VL - 137
TODO - 3
SP - 240-243
PB - Wiley
SN - 0007-1048, 1365-2141
TODO - 10.1111/j.1365-2141.2007.06561.x
TODO - multiple myeloma; free light chain ratio; prognosis
TODO - The prognostic value of baseline serum free light chain ratio (sFLCR)
was investigated in 94 multiple myeloma (MM) patients. sFLCR was
calculated as kappa/lambda or lambda/kappa, depending on the patients’
dominating monoclonal light chain. Median baseline sFLCR was 3.57 in
kappa-MM patients, 45.09 in lambda-MM. ‘High’ sFLCR (>= the observed
median value for kappa- and lambda-MM respectively) correlated with
elevated serum creatinine and lactate dehydrogenase, extensive marrow
infiltration and light chain type MM. The 5-year disease-specific
survival was 82% and 30% in patients with sFLCR lower than and equal
or greater than the median, respectively (P = 0.0001). sFLCR was an
independent prognostic factor.
ER -